中西医结合治疗新型冠状病毒肺炎重症患者的回顾性临床研究

目的回顾性分析新型冠状病毒肺炎(COVID-19)重症患者103例的临床资料,探讨中西医结合治疗COVID-19重症的临床疗效。方法收集本院2个院区2020年1月27日—2020年3月1日收治的103例治疗完整的COVID-19重型、危重型患者病历资料,包括出院、好转转出、死亡病例。根据当时的治疗方案,分为对照组和中西医结合组,对中西医结合(常规治疗+中药)组患者51例和对照组(常规治疗)患者52例的基本信息,实验室检查,肺部CT吸收情况,住院天数,转归等进行比较分析。结果中西医结合组51例,年龄(61.57±1.84)岁,男性28例,对照组52例,年龄(66.46±2.29)岁,男性24例,中西医结合组治疗后患者淋巴细胞绝对值明显升高,中西医结合治疗组患者的C反应蛋白(CRP)经治疗后有一定程度的降低,并且与对照组治疗后相比明显降低(P0.001)。对照组治疗前后患者的白蛋白未见增高且有下降趋势,中西医结合组治疗后患者白蛋白含量升高,且明显高于对照组治疗后的白蛋白含量,差异显著(P0.01),治疗后中西医结合组患者肺部吸收好转病例数明显高于对照组(P0.05)。中西医结合组患者的死亡率低于对照组,治愈率高于对照组,中西医结合治疗COVID-19重症患者,能有效减轻炎症反应,改善预后,从而提高疗效。结论中西医结合治疗COVID-19重症患者疗效确切,中药可有效减轻炎症反应,改善预后,对COVID-19的临床治疗有一定的指导意义。

Retrospective clinical study on treatment of COVID-19 patients with integrated traditional Chinese and western medicine

Objective To retrospectively analyze COVID-19 in 103 cases of clinical data, in order to explore the clinical efficacy of integrated traditional Chinese and western medicine treatment of severe COVID-19. Methods A total of 103 cases of new type of severe and critical patients with coronary pneumonia who were treated completely from January 27, 2020 to March 1, 2020 were collected in two hospital areas of Wuhan Third Hospital, including discharge, improvement and transfer out, death cases, 51 cases of patients in the treatment group of combination of traditional Chinese and western medicine (conventional treatment and traditional Chinese medicine), 52 cases in the control group (conventional treatment). The basic information, laboratory examination, lung CT absorption, and length of stay were compared and analyzed. Results A total of 51 cases in the treatment group were (61.57±1.84) years old, 28 males, 52 cases in the control group were (66.46±2.29) years old, 24 males. The absolute value of lymphocyte was significantly increased after the treatment of traditional Chinese medicine. The CRP in the treatment group was decreased to a certain extent after the treatment, and it was significantly lower than that in the control group (P<0.001). Before and after treatment, the albumin in the control group did not increase and had a downward trend. After treatment, the albumin content in the treatment group was higher than that in the control group, with a statistically significant difference (P<0.01). After treatment, the number of cases with improved lung absorption in the treatment group was significantly higher than that in the control group, with a statistically significant difference (P<0.05). Compared with the two groups, the mortality rate of the treatment group was lower than that of the control group, and the cure rate was higher than that of the control group. Conclusion COVID-19 is effective in treating severe cases of new type of severe acute coronary syndrome. Chinese medicine can effectively reduce inflammation and improve prognosis. It has certain guiding significance for the clinical treatment of COVID-19.